

# 13<sup>th</sup> Asia-Pacific Oncologists Annual Meeting

October 17-19, 2016 Kuala Lumpur, Malaysia

## Overview of cosmetic outcome of hypofractionated breast irradiation vs. chest wall irradiation in Saudi female: Single institute experience

**AbdulAziz AlHamad, Muneerah Almajed, Esam Murshid, Mohammed Aboziada and Ashraf Faraj**  
Prince Sultan Military City, Saudi Arabia

**Introduction:** Hypofractionated breast irradiation became as standard option; however, many limitations restrict such regimen like the safety for chest wall & lymphatic irradiation. In this trial, we would evaluate our result for cosmetic outcome for our breast cancer patients who have been treated with hypofractionated regimen

**Method:** We did prospective study of single institute, with total of 75 patients of breast cancer who underwent adjuvant hypofractionated radiotherapy either for breast or chest wall irradiation ± lymphatic irradiation. All patients received 42.4/16fx ± boost of 10Gy/4 fx. We did evaluate their acute dermatitis and skin pigmentation according to CTC 3.0 by the last day of radiotherapy and late skin dermatitis & skin pigmentations on follow up assessment at 6 & 18 weeks post therapy. Then we compared the outcome for both groups in regard of each outcome.

**Result:** Out of 75 female patients of breast cancer (34 patients (45.33%) had lumpectomy) vs. (41 patients 54.66% had mastectomy) for the acute dermatitis, there was no significant difference between both groups ( $p$  value=0.14), for late skin dermatitis again there was no significant difference ( $p$  value=0.159). For acute skin pigmentation, there was no significant difference ( $p$  value=0.283), while for the late skin pigmentation there was significant difference ( $p$  value=0.028) in favor of patients who had hypofractionated breast irradiation.

**Conclusion:** Our prospective trial revealed that adjuvant hypofractionated radiotherapy is safe practice for patients who underwent lumpectomy or mastectomy with caution to late skin pigmentation, further proper randomized trial is demanded for proper assessment of therapeutic & cosmetic outcome for hypofractionated radiotherapy.

### Biography

AbdulAziz AlHamad, MD FRCP (C)—Radiation Oncology is a Consultant of Radiation Oncology at Prince Sultan Military Medical City, Saudi Arabia.

aalhamad@psmmc.med.sa

### Notes: